TrialAntimicrobial agents and chemotherapy2021

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections.

Angela K Talley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.